The biology and plasticity of residual disease

Brief Synopsis

Breast cancer neoadjuvant treatment is becoming a more and more prevalent, with the management of patients with residual disease also becoming more complex. Clinical trials specifically designed for those with residual disease are now common, however, much less is known about the biology of residual disease and how it was altered by the treatment. I will cover a number of the studies that have specifically studied breast tumors before and after neoadjuvant treatment, with a focus on immune cell dynamics, EMT, and the plasticity of tumor cells after treatment.